更新于：2024-05-01
Carbon Dioxide
二氧化碳
更新于：2024-05-01
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-07-18) |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式CO2 |
InChIKeyCURLTUGMZLYLDI-UHFFFAOYSA-N |
CAS号124-38-9 |
关联
25
项与 二氧化碳 相关的临床试验Standard vs. Lower Pressure Pneumoperitoneum in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial
Applied Physiology of Oxygen Toxicity: Mechanisms in Humans
Methodological trial to investigate the dose-response relationship, test-retest reliability and tolerance to repeated exposure of the 35% carbon dioxide experimental panic challenge in CO2-sensitive healthy volunteers - Methodological optimization of the CO2 challenge
100 项与 二氧化碳 相关的临床结果
登录后查看更多信息
100 项与 二氧化碳 相关的转化医学
登录后查看更多信息
100 项与 二氧化碳 相关的专利（医药）
登录后查看更多信息
464
项与 二氧化碳 相关的文献（医药）2023-12-16Annals of vascular surgery
Safety, effectiveness and pitfalls of carbon dioxide (CO2) routine use as a contrast agent for endovascular abdominal aortic repair.
Article
作者: Simone Quaglino ; Emanuele Ferrero ; Michelangelo Ferri ; Paola Manzo ; Andrea Viazzo ; Michela Lanza ; Andrea Ricotti ; Andrea Gaggiano
OBJECTIVES:
Despite the evidence of good performance, CO2 routine employment as a contrast agent for endovascular procedures is far from being adopted with its use currently limited to patients with renal impairment and known allergy to iodinated contrast medium (ICM). The purpose of our study is to evaluate the safety and effectiveness of CO2 guided EVAR in a standard population and to assess the rationale for a future widespread use.
METHODS:
We retrospectively collected data of every patient who underwent CO2 guided standard EVAR from September 2020 to May 2021 and compared them with the data of every patient who underwent EVAR using ICM from December 2019 to August 2020 in our unit. The selection of the contrast medium was not based on any preoperative factor as the contrast medium was routinely used in every patient in both periods. The primary endpoint of the study was the technical success rate. Secondary endpoints were the early and late complication rates, radiation exposure and renal function impairment.
RESULTS:
49 patients underwent ICM guided EVAR and 52 patients underwent CO2 guided EVAR in our unit in the time frames specified above. The technical success rate was 100% in both groups with no accidental coverage of any target vessel. Intraoperative endoleaks were observed in 14% of ICM patients and 25% of CO2 patients. The radiation exposure was higher in the CO2 group if compared to the ICM group (311.48 vs 159.86 median mGy/cm2 - p < 0.001). The incidence of post-operative acute kidney injury was low and similar in the two groups. No significant worsening over time of the renal function has been reported in both groups.
CONCLUSIONS:
EVAR can be safely performed under CO2 guidance without the integration of any quantity of ICM but with an increase in radiation exposure. The nephroprotective role of CO2 guided EVAR in a standard population is unclear and the same role in renal impaired patients should be validated with further studies on selected populations.
2023-11-13JMIR research protocols
The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial.
Article
作者: Yoshiaki Tadokoro ; Daisuke Takeda ; Izumi Saito ; Nanae Yatagai ; Yasumasa Kakei ; Masaya Akashi ; Takumi Hasegawa
BACKGROUND:
Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO2) paste in relieving pain in patients after neck dissection.
OBJECTIVE:
This will be the first clinical study to compare the efficacy of CO2 paste with placebo in relieving postoperative pain in patients who underwent neck dissection.
METHODS:
We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO2 paste and control groups. Patients in the CO2 paste group will have the CO2 paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University.
RESULTS:
The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO2 paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025.
CONCLUSIONS:
This trial will provide exploratory evidence of the efficacy and safety of CO2 paste in relieving pain in patients after neck dissection.
TRIAL REGISTRATION:
Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
DERR1-10.2196/50500.
2023-10-01Food microbiology
Impact of sodium chloride and carbon dioxide on conidial germination and radial growth of Penicillium camemberti
Article
作者: Valle, Marion ; Nguyen Van Long, Nicolas ; Jany, Jean-Luc ; Koullen, Loona ; Rigalma, Karim ; Vasseur, Valerie ; Huchet, Veronique ; Coroller, Louis
Penicillium camemberti is a domesticated species adapted to the dairy environment, which is used as adjunct cultures to ripen soft cheeses. A recent population genomics analysis on P. camemberti revealed that P. camemberti is a clonal lineage with two varieties almost identical genetically but with contrasting phenotypes in terms of growth, color, mycotoxin production and inhibition of contaminants. P. camemberti variety camemberti is found on Camembert and Brie cheeses, and P. camemberti variety caseifulvum is mainly found on other cheeses like Saint-Marcellin and Rigotte de Condrieu. This study aimed to evaluate the impact of water activity (aw) reduced by sodium chloride (NaCl) and the increase of carbon dioxide (CO2) partial pressure, on conidial germination and growth of two varieties of P. camemberti: var. Camemberti and var. Caseifulvum. Mathematical models were used to describe the responses of P. camemberti strains to both abiotic factors. The results showed that these genetically distant strains had similar responses to increase in NaCl and CO2 partial pressure. The estimated cardinal values were very close between the strains although all estimated cardinal values were significantly different (Likelihood ratio tests, pvalue = 0.05%). These results suggest that intraspecific variability could be more exacerbated during fungal growth compared with conidial germination, especially in terms of macroscopic morphology. Indeed, var. Caseifulvum seemed to be more sensitive to an increase of CO2 partial pressure, as shown by the fungal morphology, with the occurrence of irregular outgrowths, while the morphology of var. Camemberti remains circular. These data could make it possible to improve the control of fungal development as a function of salt and carbon dioxide partial pressure. These abiotic factors could serve as technological barriers to prevent spoilage and increase the shelf life of cheeses. The present data will allow more precise predictions of fungal proliferation as a function of salt and carbon dioxide partial pressure, which are significant technological hurdles in cheese production.
100 项与 二氧化碳 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| - | 批准上市 | 美国 更多 | |
| 呼吸系统疾病 | 无进展 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 鬱範淵簾鬱鏇獵鹽襯遞(襯網淵憲襯膚鑰蓋糧糧) = 襯鹽鑰觸廠衊願糧顧鏇 鏇餘顧衊鬱鏇繭膚願觸 (淵積願願積窪窪築餘壓, 壓鹽衊膚鹹糧繭膚選窪 ~ 鏇範鏇鬱齋範繭願窪餘) 更多 | - | 2018-05-01 | |||
临床4期 | - | 180 | Air insufflation (Air for Insufflation) | 願築衊餘蓋齋艱積簾製(衊顧遞鹽醖餘餘製鑰艱) = 糧獵網鏇鏇餘窪積壓製 獵齋鬱窪淵襯齋鬱構構 (網鹽鏇衊糧鏇願鏇艱鏇, 醖憲壓齋淵鏇憲選壓鬱 ~ 鬱觸築積網齋齋艱獵壓) 更多 | - | 2022-01-19 | |
(Carbon Dioxide Gas for Insufflation) | 願築衊餘蓋齋艱積簾製(衊顧遞鹽醖餘餘製鑰艱) = 糧醖鬱膚構廠衊構鬱選 獵齋鬱窪淵襯齋鬱構構 (網鹽鏇衊糧鏇願鏇艱鏇, 遞廠憲遞淵積壓廠獵鬱 ~ 憲襯壓觸鏇鬱膚衊憲壓) 更多 | ||||||
N/A | - | 71 | (Bronchoscopic Cryosurgery with Carbon Dioxide) | 遞醖遞鏇膚鬱繭網鹽餘(獵積憲膚壓夢顧願鹽構) = 願鏇積夢網壓築壓膚齋 襯夢夢遞壓鹽鏇蓋淵積 (艱顧廠遞艱膚選範鹹鏇 ) 更多 | - | 2016-12-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用